Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Supreme Court - Phil Roeder

Bio IT World just published an article stating that the Myriad Supreme Court case will have little to no effect on whole genome sequencing. “As WGS involves determining the sequence of an individual’s entire genome, there is concern in many quarters that WGS could violate essentially every patent covering an isolated human DNA sequence—of which there are thousands. Indeed, this concern has been raised by scholars, policy analysts and lawyers, including before the Federal Circuit Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Traditional Knowledge and Genetic Resources: India Misses the Mark

2499660451_634e5f1235

India recently asked the global community for comments on its “Draft Guidelines for Processing of Patent Applications Relating to Traditional Knowledge and Biological Material.”  BIO was very active in their support of the goals of the Convention on Biological Diversity and “believes that a practical and workable Access and Benefit Sharing regime will benefit both the owner and the user of genetic resources and help countries to utilize their resources to develop their economies.”  BIO Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The ‘Access to Medicines’ Debate: Throwing Patients Without Cures Under the Proverbial Bus

Access to Medicines

The vast majority of the world’s patients remain completely forgotten in the ‘access to medicines’ debate.   Many fail to understand how that elimination will affect the development of the cures and treatments of tomorrow, especially for rare diseases, cancers, and other serious unmet medical conditions. The Forgotten: 25 million Americans suffer from nearly 7000 rare diseases.  30 million European Union citizens suffer from between 6000 to 8000 rare diseases, 80% of which are of genetic origin Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Biotech Patenting Event: BIO’s 2012 Fall IPCC in Charleston, South Carolina

charleston

BIO’s 2012 Fall IPCC Conference event on November 12-14 gathers biotech in-house counsels to provide and discuss relevant IP developments.  The Honorable Jimmie V. Reyna, Circuit Judge for the United States Court of Appeals for the Federal Circuit keynotes this year’s program along with the Honorable Judge Sally Gardner Lane, Administrative Patent Judge, Trial Division, Board of Patent Appeals and Interferences. Find program topics and speakers below.  Click here for the full agenda.   Picking the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Finding Value in Early Stage Collaborations at the BIO Technology Transfer Symposium

Bridge

The BIO Technology Transfer Symposium dissects recent academia-industry collaborations and evaluates the value in early stage biotechnology investments.  The event occurs in San Francisco on October 8th ahead of the BIO Investor Forum and provides a unique opportunity for bringing academia, industry, and the investment community together. This year’s event is headlined by Tom Thornton from the Cleveland Clinic, a leading academic medical center.  The first panel highlights the collaboration between Duke Translational Research Institute Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,